🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the effort against superbug strains of the infection, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are on the rise worldwide, with data suggesting over 82 million instances each year. Particularly high rates are seen in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the context of rising global incidence, the spread of superbugs and the extremely scarce treatment choices at this time.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists believe that specific application of this new drug will help delay the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This milestone signifies a huge turning point in the management of superbug gonorrhoea, which previously has been staying ahead of antibiotic development.”

Research Study Outcomes and Worldwide Availability

According to findings detailed in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which involves two antibiotics. The study enrolled over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to license and sell the drug in a wide range of developing nations.

Doctors on the front lines have voiced hope. Having a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for managing the epidemic. This is deemed crucial to alleviate the strain of the illness for people and to prevent the spread of extremely resistant gonorrhoea around the world.